Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy-Reference-Cited by-同舟云学术

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

Published:2020-04-01 Issue:4 Volume:36 Page:254-255
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Taiwo Babafemi O.¹,Quiñones-Mateu Miguel E.²,Smith Kimberly³,Zheng Lu⁴,Gulick Roy⁵,Nyaku Amesika N.⁶,Sax Paul E.⁷,Ha Belinda³,Kumwenda Johnstone⁸,Olefsky Maxine⁴,Godfrey Catherine⁹,Wallis Carole¹⁰

Affiliation:

1. Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

2. Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.

3. ViiV Healthcare, Research Triangle Park, North Carolina.

4. Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

5. Division of Infectious Diseases, Weill Cornell Medical College, New York, New York.

6. Division of Infectious Diseases, Rutgers University, Newark, New Jersey.

7. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts.

8. Department of Medicine, University of Malawi, Zomba, Malawi.

9. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.

10. Lancet Laboratories, Johannesburg, South Africa.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2019.0253

Reference4 articles.

1. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

2. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL

3. Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism

4. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine;Clinical Infectious Diseases;2024-03-11

2. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Expert Opinion on Drug Safety;2021-02-24

3. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy;Journal of Antimicrobial Chemotherapy;2020-07-30